BioSpace News Archive

Intec Pharma Ltd. announced the pricing of its previously announced underwritten public offering of 16,250,000 ordinary shares and warrants to purchase up to 16,250,000 ordinary shares, at a public offering price of $0.40 per ordinary share.

SAGA Diagnostics AB, a cancer liquid biopsy and genomic testing company focused on precision oncology and non-invasive ultrasensitive monitoring of cancer patients, today announces it has entered service agreements with the international pharmaceutical company Servier, based in Paris, France.

Twistle, a company that helps health systems automate personalized education and care communications with their patients, today announces that Providence Saint Joseph Health System (Providence) and ChristianaCare, two of the nation’s most innovative health systems, are now strategic investors as well as significant customers.

Myomo, Inc. (NYSE American: MYO), a commercial stage medical robotics company that offers expanded mobility for those suffering from neurological disorders and upper limb paralysis, today announced following approval of a reverse stock split range and authorized share reduction by stockholders at a special meeting of stockholders earlier today,

New Jersey-based dental specialist to lead the premier organization for prosthodontics

Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmune disease and cancer, today announced that it intends to offer and sell shares of its common stock and, to certain investors in lieu thereof, pre-funded warrants to purchase shares of its common stock, in an underwritten public offering

Aprecia, the 3DP Pharmaceutical Company, announced today that Amol Matharu, Ph.D., has been named the company’s Chief Scientific Officer. Matharu will lead the company’s Research & Development function, the foundation for which is Aprecia’s proprietary ZipDose® Technology, the world’s first and only commercially viable 3DP technology platform and is used in the first FDA-approved 3D-printed drug.

ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, February 14, 2020 to discuss its 2019 operating results.

Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year 2019 versus comparable periods in 2018.

Intec Pharma Ltd. announced that it intends to offer and sell a combination of ordinary shares and warrants to purchase ordinary shares in an underwritten public offering.